Evidence map›Paper›PMID 25028721›Full record

ArticleBioinformatics (Oxford, England)2014

Modeling time-dependent transcription effects of HER2 oncogene and discovery of a role for E2F2 in breast cancer cell-matrix adhesion.

Aliccia Bollig-Fischer, Luca Marchetti, Cristina Mitrea, Jiusheng Wu, Adéle Kruger, Vincenzo Manca, Sorin Drăghici

Open access · bronzeAbstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. RETRACTED: Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Breast CancerMolecular therapy : the journal of the American Society of Gene Therapy · 2019
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Aliccia Bollig-FischerBarbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI 48201, USA, Department of Computer Science, University of Verona, 37134 Verona, Italy, The Microsoft Research-University of Trento Centre for Computational and Systems Biology, 38068 Rovereto, Italy, Department of Computer Science, Wayne State University and Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA Barbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI 48201, USA, Department of Computer Science, University of Verona, 37134 Verona, Italy, The Microsoft Research-University of Trento Centre for Computational and Systems Biology, 38068 Rovereto, Italy, Department of Computer Science, Wayne State University and Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA.
Luca MarchettiBarbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI 48201, USA, Department of Computer Science, University of Verona, 37134 Verona, Italy, The Microsoft Research-University of Trento Centre for Computational and Systems Biology, 38068 Rovereto, Italy, Department of Computer Science, Wayne State University and Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA Barbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI 48201, USA, Department of Computer Science, University of Verona, 37134 Verona, Italy, The Microsoft Research-University of Trento Centre for Computational and Systems Biology, 38068 Rovereto, Italy, Department of Computer Science, Wayne State University and Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA.
Cristina MitreaBarbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI 48201, USA, Department of Computer Science, University of Verona, 37134 Verona, Italy, The Microsoft Research-University of Trento Centre for Computational and Systems Biology, 38068 Rovereto, Italy, Department of Computer Science, Wayne State University and Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA.
Jiusheng WuBarbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI 48201, USA, Department of Computer Science, University of Verona, 37134 Verona, Italy, The Microsoft Research-University of Trento Centre for Computational and Systems Biology, 38068 Rovereto, Italy, Department of Computer Science, Wayne State University and Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA Barbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI 48201, USA, Department of Computer Science, University of Verona, 37134 Verona, Italy, The Microsoft Research-University of Trento Centre for Computational and Systems Biology, 38068 Rovereto, Italy, Department of Computer Science, Wayne State University and Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA.
Adéle KrugerBarbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI 48201, USA, Department of Computer Science, University of Verona, 37134 Verona, Italy, The Microsoft Research-University of Trento Centre for Computational and Systems Biology, 38068 Rovereto, Italy, Department of Computer Science, Wayne State University and Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA.
Vincenzo MancaBarbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI 48201, USA, Department of Computer Science, University of Verona, 37134 Verona, Italy, The Microsoft Research-University of Trento Centre for Computational and Systems Biology, 38068 Rovereto, Italy, Department of Computer Science, Wayne State University and Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA.
Sorin DrăghiciBarbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI 48201, USA, Department of Computer Science, University of Verona, 37134 Verona, Italy, The Microsoft Research-University of Trento Centre for Computational and Systems Biology, 38068 Rovereto, Italy, Department of Computer Science, Wayne State University and Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA Barbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University, Detroit, MI 48201, USA, Department of Computer Science, University of Verona, 37134 Verona, Italy, The Microsoft Research-University of Trento Centre for Computational and Systems Biology, 38068 Rovereto, Italy, Department of Computer Science, Wayne State University and Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA.
University of Trento · ITUniversity of Verona · ITWayne State University · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
Enhancing neoadjuvant chemotherpay responses with targeted T cellsR01CA140314 · NCI · WAYNE STATE UNIVERSITY · PI BEPLER, GEROLD · 2010 to 2015
$2.5M
Pathway-Guide: A novel tool for the analysis of signaling and metabolic pathwaysR42GM087013 · NIGMS · ADVAITA CORPORATION · PI DRAGHICI, SORIN · 2011 to 2013
$2.2M
Novel methods for the analysis of gene signaling pathways with applications in obR01DK089167 · NIDDK · WAYNE STATE UNIVERSITY · PI DRAGHICI, SORIN · 2010 to 2013
$1.2M
A Novel Method for Signaling Pathway AnalysisR41GM087013 · NIGMS · ADVAITA CORPORATION · PI DRAGHICI, SORIN · 2009 to 2009
$146k
NCI NIH HHS P30 CA022453NCI NIH HHS P30CA022453NCI NIH HHS R01 CA140314NIDDK NIH HHS R01 DK089167NIGMS NIH HHS 42GM087013
6 · The paper itself

Abstract

motivationOncogenes are known drivers of cancer phenotypes and targets of molecular therapies; however, the complex and diverse signaling mechanisms regulated by oncogenes and potential routes to targeted therapy resistance remain to be fully understood. To this end, we present an approach to infer regulatory mechanisms downstream of the HER2 driver oncogene in SUM-225 metastatic breast cancer cells from dynamic gene expression patterns using a succession of analytical techniques, including a novel MP grammars method to mathematically model putative regulatory interactions among sets of clustered genes.

resultsOur method highlighted regulatory interactions previously identified in the cell line and a novel finding that the HER2 oncogene, as opposed to the proto-oncogene, upregulates expression of the E2F2 transcription factor. By targeted gene knockdown we show the significance of this, demonstrating that cancer cell-matrix adhesion and outgrowth were markedly inhibited when E2F2 levels were reduced. Thus, validating in this context that upregulation of E2F2 represents a key intermediate event in a HER2 oncogene-directed gene expression-based signaling circuit. This work demonstrates how predictive modeling of longitudinal gene expression data combined with multiple systems-level analyses can be used to accurately predict downstream signaling pathways. Here, our integrated method was applied to reveal insights as to how the HER2 oncogene drives a specific cancer cell phenotype, but it is adaptable to investigate other oncogenes and model systems. AVAILABILITY AND IMPLEMENTATION: Accessibility of various tools is listed in methods; the Log-Gain Stoichiometric Stepwise algorithm is accessible at http://www.cbmc.it/software/Software.php.

Indexed as

Gene Expression Regulation, NeoplasticGenes, erbB-2Breast NeoplasmsCell AdhesionCell Line, TumorCell-Matrix JunctionsE2F2 Transcription FactorFemaleGene Knockdown TechniquesHumansModels, GeneticProto-Oncogene MasSignal TransductionTranscription, GeneticTranscriptomeUp-RegulationE2F2 protein, humanE2F2 Transcription FactorMAS1 protein, humanProto-Oncogene Mas

Identifiers

PMID25028721
PMCPMC4201152
OpenAlexW2087754565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.